Skip to main content
. 2024 Jun 6;38(7):1477–1487. doi: 10.1038/s41375-024-02287-7

Fig. 1. Meta-analysis of outcome of LR and MR arms of trials included in ETV6::RUNX1 therapy intensity study.

Fig. 1

A 5-year event-free survival (%), B 5-year overall survival (%), C 5-year cumulative incidence of relapse (%), D 5-year cumulative incidence of death in remission (%). EFS event-free survival, OS overall survival, CIR clinical incidence of relapse, DCR death in complete remission, CCLSG Children’s Cancer and Leukemia Study Group, CoALL Childhood Acute Lymphoblastic Leukemia, NOPHO Nordic Society of Pediatric Hematology and Oncology, UKALL United Kingdom Acute Lymphoblastic Leukemia; AIEOP-BFM, Associazione Italiana di Ematologia e Oncologia Pediatrica and Berlin Frankfurt Münster; ALL IC-BFM Acute Lymphoblastic Leukemia Intercontinental-Berlin Frankfurt Münster, DCOG Dutch Childhood Oncology Group, JACLS Japan Childhood Leukemia Study Group.